Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.74 HKD | +1.08% | +8.41% | +2.47% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.47% | 311M | - | ||
+9.42% | 115B | B+ | ||
+11.84% | 106B | B+ | ||
-1.05% | 21.96B | B | ||
-14.15% | 21.84B | B+ | ||
-5.29% | 19.21B | A- | ||
-4.16% | 18.08B | B | ||
-38.29% | 17.71B | A- | ||
+7.99% | 14.32B | C+ | ||
+36.24% | 12.42B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2256 Stock
- Ratings Abbisko Cayman Limited